Autoimmune Pancreatitis (AIP)

Autoimmune pancreatitis (AIP) is a special kind of chronic inflammation of the pancreas that happens when the immune system mistakenly attacks the pancreas. It often causes painless yellowing of the eyes/skin (obstructive jaundice) or looks like a lump on scans that can be confused with pancreatic cancer. Under the microscope, doctors see dense immune cells around the ducts, scarring (“fibrosis”), and, in one common form, many plasma cells that carry a marker called IgG4. Most people improve quickly with steroid medicines, which is a key clinical clue. The formal international criteria for diagnosing AIP use five pillars: pancreas imaging, duct imaging, blood tests (serology), findings in other organs, and tissue biopsy—plus the patient’s response to steroids when cancer has been carefully excluded. PubMed+2PMC+2

Autoimmune pancreatitis is an uncommon, long-lasting inflammation of the pancreas driven by the immune system. There are two main types. Type 1 AIP is part of a broader condition called IgG4-related disease (IgG4-RD) that can also involve the bile ducts, salivary glands, kidneys and more. Type 2 AIP is limited to the pancreas and is often linked with inflammatory bowel disease. Typical features include swollen pancreas on imaging, very high IgG4 levels (usually in type 1), and a biopsy showing “storiform” fibrosis (whorled scarring), many IgG4-positive plasma cells, and “obliterative phlebitis” (vein inflammation). Importantly, AIP often responds dramatically to steroids. PMC+2Darmzentrum Bern+2

Autoimmune pancreatitis is a special kind of long-lasting inflammation in the pancreas caused by a misdirected immune response. Instead of protecting you, parts of your immune system attack the pancreas, which can make the gland swollen, stiff, and sometimes “sausage-shaped” on scans. Many people respond very well to steroid medicines, which helps doctors recognize this condition. There are two main forms: Type 1 AIP, which is part of a broader illness called IgG4-related disease that can involve many organs, and Type 2 AIP, which usually affects only the pancreas and often occurs in people with inflammatory bowel disease. Because AIP can look like pancreatic cancer or other types of pancreatitis on scans and blood tests, doctors use a combination of features—imaging, blood markers (like IgG4), other-organ involvement, tissue biopsy, and response to steroids—to make a confident diagnosis. PMC+2Lippincott Journals+2

Other names

Doctors and articles may use these alternate names. They largely point to the same condition or its subtypes:
Autoimmune pancreatitis; IgG4-related pancreatitis; Type 1 AIP (IgG4-related); Type 2 AIP (idiopathic duct-centric pancreatitis); lymphoplasmacytic sclerosing pancreatitis; IgG4-related disease (pancreatic involvement); steroid-responsive chronic pancreatitis. These terms reflect how AIP behaves, what it looks like under the microscope, and its link to IgG4-related disease. PMC+1

Types

Type 1 AIP (IgG4-related): This is the most common form worldwide. It often raises blood IgG4 levels and can involve other organs like the bile ducts, salivary glands, kidneys, and lymph nodes. Under the microscope, the tissue shows dense immune-cell clusters, storiform (whorled) fibrosis, and inflammation around veins (obliterative phlebitis). Relapses are more common in Type 1 than Type 2. WJGNet+2PMC+2
Type 2 AIP (idiopathic duct-centric pancreatitis): Usually limited to the pancreas and not linked to IgG4. It often appears in younger patients and is more frequently associated with ulcerative colitis or other forms of IBD. Relapses are uncommon after treatment. PMC+1

Causes / risk factors / associations

Strictly speaking, AIP is immune-mediated rather than caused by a single trigger. Clinically, doctors consider the following associations and contexts that can raise suspicion or coexist with AIP:

1. IgG4-related disease (IgG4-RD): Type 1 AIP is the pancreatic face of this multi-organ condition. PMC

2. Male sex and middle-to-older age: Type 1 AIP skews toward older men in many series. WJGNet

3. Asian ancestry in some cohorts: Earlier descriptions noted higher recognition in Japan; AIP is now identified worldwide. CGH Journal

4. Inflammatory bowel disease (IBD): Stronger link to Type 2 AIP; many have ulcerative colitis. PMC

5. Autoimmune conditions elsewhere: Salivary and lacrimal gland swelling, autoimmune cholangitis, thyroiditis may travel with Type 1 AIP. PMC+1

6. Elevated serum IgG4: Helpful clue (mainly Type 1), but not perfect—some patients have normal levels. WJGNet

7. Genetic susceptibility (HLA links): Research suggests certain HLA backgrounds may contribute, though not diagnostic alone. PMC

8. Microbial/immune triggers (hypothesized): Proposed but unproven triggers that tilt immunity toward a fibro-inflammatory response. PMC

9. Biliary disease (IgG4-sclerosing cholangitis): Often coexists and can cause jaundice. PMC

10. Kidney involvement (IgG4-tubulointerstitial nephritis): Signals systemic IgG4-RD with pancreatic disease. PMC

11. Retroperitoneal fibrosis: A known IgG4-RD partner lesion. PMC

12. Lymph-node enlargement in IgG4-RD: Non-specific but supportive when seen with AIP features. PMC

13. Smoking and alcohol are not causes of AIP: They matter for other pancreatitis types but do not explain immune-mediated AIP. (Important to avoid confusion.) niddk.nih.gov

14. Pancreatic mass-like swelling on imaging: Not a cause, but a typical AIP appearance that prompts evaluation. Mayo Clinic

15. High ESR/CRP (inflammation markers): Indicate inflammation that can accompany AIP but are non-specific. NCBI

16. Relapsing pattern after steroid taper (mainly Type 1): Reflects underlying immune activity. PMC

17. Obstructive jaundice due to bile-duct involvement: Common presentation that raises suspicion for AIP vs cancer. PMC

18. Pancreatic exocrine insufficiency (EPI) in chronic disease: A downstream effect when AIP leads to chronic damage. ScienceDirect

19. Other organ pain/swelling in IgG4-RD (salivary, lacrimal, orbital, lung): Helps “connect the dots.” Oxford Academic

20. Response to steroids: Not a cause, but a diagnostic clue built into modern criteria because AIP is typically steroid-responsive. PMC

Common symptoms

1. Upper belly pain: Often dull or aching; may be mild or moderate. PubMed

2. Painless jaundice: Yellow eyes/skin when bile ducts are inflamed or narrowed. PMC

3. Dark urine and pale stools: From reduced bile flow into the intestine. PMC

4. Itching (pruritus): Bile buildup can irritate the skin. PMC

5. Weight loss: Inflammation, poor appetite, or malabsorption may contribute. PubMed

6. Nausea or vomiting: Especially during flares of pancreatic inflammation. niddk.nih.gov

7. Fatigue: Common with chronic inflammation. NCBI

8. Diarrhea or greasy stools (steatorrhea): If pancreatic enzyme output falls (exocrine insufficiency). ScienceDirect

9. Dry mouth or swollen salivary glands: If IgG4-RD affects these glands. PMC

10. Abdominal fullness/bloating: From gland swelling or bile-duct blockage. PubMed

11. Back pain: Pancreatic pain may radiate to the back. niddk.nih.gov

12. Low-grade fever: Non-specific sign of inflammation. NCBI

13. New-onset or worsening diabetes: If long-standing inflammation harms insulin-making cells. niddk.nih.gov

14. Eye or orbital symptoms (rare): Part of systemic IgG4-RD in some patients. Oxford Academic

15. Relapsing pattern of symptoms after tapering steroids (Type 1): Suggests ongoing immune activity. PMC

Diagnostic tests

A) Physical-exam based (bedside)

1. General inspection for jaundice and scratching marks: Simple clues of bile-duct involvement. PMC

2. Abdominal palpation for tenderness or fullness: Non-specific but guides urgent imaging. niddk.nih.gov

3. Salivary and lacrimal gland check: Swelling suggests multi-organ IgG4-RD. PMC

4. Lymph-node exam: Enlarged nodes may accompany IgG4-RD. PMC

B) “Manual tests (office-based procedures and practical assessments)

5. Nutritional assessment and stool fat evaluation: Looks for malabsorption from pancreatic enzyme deficiency. ScienceDirect

6. Trial of pancreatic enzymes for steatorrhea: Symptom improvement supports exocrine insufficiency from chronic AIP. ScienceDirect

7. Structured steroid trial (used cautiously): Part of historical criteria (HISORt); improvement in symptoms/imaging supports AIP when cancer is reasonably excluded. PMC

Note: In pancreatitis, there aren’t classic “manual maneuvers” like in orthopedics. Here, “manual” reflects practical bedside/office assessments and the carefully supervised response-to-steroids clue used in recognized criteria sets.

C) Laboratory and pathology tests

8. Serum IgG4 level: Often elevated in Type 1; normal does not exclude AIP. WJGNet

9. Total IgG and IgG subclasses: Broader look at immunoglobulins when IgG4 alone is borderline. PMC

10. Liver tests (bilirubin, ALP, GGT, ALT/AST): Detect cholestasis from IgG4-sclerosing cholangitis. PMC

11. Inflammation markers (ESR/CRP): Support an inflammatory process but are non-specific. NCBI

12. Pancreatic enzymes (amylase/lipase): May be normal or mildly elevated; not definitive for AIP. niddk.nih.gov

13. Tumor marker CA 19-9 (to help exclude cancer): Can be elevated in biliary obstruction; must be interpreted with imaging and clinical context. PubMed

14. EUS-guided core biopsy of the pancreas: Looks for the classic lymphoplasmacytic infiltrate, storiform fibrosis, and IgG4-positive plasma cells; helps rule out cancer. CGH Journal

15. Bile-duct biopsy (if strictures present): Can confirm IgG4-related sclerosing cholangitis. PMC

D) Electrodiagnostic tests

16. No pancreas-specific electrodiagnostics exist: Unlike nerve or muscle diseases, AIP diagnosis does not rely on ECG/EEG/EMG-type studies; doctors focus on imaging, labs, and biopsy. (Important clarification.) Lippincott Journals

E) Imaging and endoscopic tests

17. Contrast-enhanced CT scan: May show a diffusely enlarged “sausage-shaped” pancreas with a rim (“capsule-like” halo) or focal mass-like swelling; helps track duct/bile changes. Mayo Clinic

18. MRI/MRCP: Excellent for seeing narrowed pancreatic and bile ducts, and soft-tissue changes without radiation. Lippincott Journals

19. Endoscopic ultrasound (EUS): High-detail look at the pancreas and a platform to take core biopsies safely. CGH Journal

20. ERCP (endoscopic retrograde cholangiopancreatography): Maps duct narrowings; used more selectively now due to less-invasive MRCP and biopsy options, but still valuable in some cases. PMC

Non-pharmacological treatments (therapies and others)

(Each item includes: description ~plain English, purpose, mechanism.)

1) Education & shared plan – Learn what AIP is, how it mimics cancer, and why steroids/monitoring matter. A simple care plan (medicine schedule, lab/imaging checkpoints, red-flags) reduces anxiety and helps adherence. Purpose: empower you to participate in care. Mechanism: better adherence → fewer relapses and safer steroid taper. PMC+1

2) Alcohol abstinence – Even though AIP is immune-driven, alcohol worsens pancreatitis risks and future flares. Stopping alcohol lowers recurrent attacks and disease progression. Purpose: reduce pancreatic stress. Mechanism: removes a known pancreatic toxin that amplifies inflammation. Gastro Journal+1

3) Stop smoking – Smoking independently speeds chronic pancreatitis progression; together with alcohol the risk is additive. Purpose: slow damage to the pancreas and reduce complications like exocrine insufficiency. Mechanism: tobacco toxins promote fibrosis and inflammation. PMC+1

4) Nutrition counseling – Work with a dietitian for frequent, balanced meals tailored to symptoms. Low-fat is not automatically required if enzymes are optimized; instead, aim for adequate calories and protein, and avoid very high-fiber meals if they worsen steatorrhea. Purpose: prevent malnutrition and weight loss. Mechanism: matching diet + enzymes improves absorption. PubMed+1

5) Pancreatic enzyme replacement therapy (PERT) when needed – If tests or symptoms show exocrine pancreatic insufficiency (EPI) (greasy stools, weight loss), enzymes at meals improve digestion and nutrition. Purpose: correct fat and protein malabsorption. Mechanism: replaces missing pancreatic enzymes. PubMed

6) Vitamin/mineral repletion – Because chronic pancreatitis/EPI can cause deficiencies (A, D, E, K; calcium; trace elements), screen and supplement appropriately. Purpose: prevent anemia, bone loss and neuropathy. Mechanism: targeted replacement based on labs. PubMed

7) Bone health protection on steroids – If you’ll take glucocorticoids for >3 months, build bone protection: weight-bearing exercise, fall risk reduction, adequate calcium (1,000–1,200 mg/day) and vitamin D (per labs, often 1,000–2,000 IU/day); consider bisphosphonates if fracture risk is elevated. Purpose: prevent steroid-induced osteoporosis. Mechanism: counteracts steroid-related bone loss. PubMed+2Endocrine+2

8) Infection prevention while immunosuppressed – Discuss Pneumocystis jirovecii prophylaxis if prednisone ≥20 mg/day for ≥4 weeks with other risk factors or added immunosuppression. Keep vaccines current (e.g., influenza, pneumococcal) per local guidance. Purpose: reduce serious infections during high-dose therapy. Mechanism: antimicrobial prophylaxis and immunization. JAMA Network+1

9) Diabetes monitoring & management – Steroids can raise blood sugar; AIP and chronic pancreatitis can cause diabetes. Purpose: avoid hyperglycemia complications. Mechanism: home glucose checks, diet, meds/insulin as needed. PMC

10) Pain strategies – Optimize enzymes and nutrition first; consider step-wise analgesia and non-drug methods (heat packs, paced breathing, gentle activity). Purpose: safer pain control. Mechanism: treat drivers (malabsorption/inflammation) before escalating analgesics. MDPI

11) Psychological support – Chronic disease increases stress/anxiety. Brief counseling or support groups improve coping and adherence. Purpose: improve quality of life. Mechanism: skills and social support. PMC

12) Exercise program – Regular, tolerable activity aids mood, bone density (if on steroids), and weight stability. Purpose: maintain function and bone. Mechanism: mechanical loading and metabolic benefits. Rheumatology Advisor

13) Medication review – Coordinate all prescribers to avoid drug interactions (e.g., immunosuppressants), plan GI protection when appropriate, and align steroid taper. Purpose: safety. Mechanism: reduce adverse events. PMC

14) Sun protection & skin checks (on steroids/immunosuppressants) – Immunosuppression can increase skin infection risk and photosensitivity with some agents. Purpose: reduce preventable side effects. Mechanism: behavioral prevention. Spandidos Publications

15) Structured relapse surveillance – Track symptoms, labs (IgG4 when relevant), and imaging intervals based on your specialist’s plan because relapse is common in type 1 AIP. Purpose: catch relapse early. Mechanism: scheduled follow-up with predefined triggers to treat. BioMed Central

16) Enteral nutrition when oral intake is inadequate – In severe malnutrition or repeated flares, tube feeding may be considered to maintain nutrition. Purpose: prevent muscle loss and vitamin deficiency. Mechanism: safe delivery of calories and micronutrients. PubMed

17) Biliary drainage for obstructive jaundice – If bile ducts are very tight (IgG4-related sclerosing cholangitis), temporary endoscopic stents may be used alongside steroids. Purpose: relieve jaundice/cholangitis while steroids take effect. Mechanism: mechanical decompression of ducts. PLOS

18) Avoid unnecessary prolonged stents – Many IgG4-related biliary strictures improve with steroids; stents are often short-term or avoidable unless severe jaundice/infection. Purpose: reduce stent-related complications. Mechanism: prioritize steroid response. GIE Journal

19) Vaccination planning before rituximab/biologics – Get indicated non-live vaccines before B-cell depletion, when possible, to improve response. Purpose: infection prevention. Mechanism: timing vaccine when immune system can respond. PubMed

20) Multidisciplinary care – Gastroenterology, radiology, pathology, rheumatology/hepatology and nutrition together lower misdiagnosis risk and optimize treatment. Purpose: safer, faster diagnosis and tailored therapy. Mechanism: criteria-driven team decisions (ICDC + IgG4-RD RCD 2020). PubMed+1

---

Drug treatments

1) Prednisone/Prednisolone (first-line to induce remission) – Class: glucocorticoid. Dose/time: commonly 0.4–0.6 mg/kg/day (often 30–40 mg/day) for 2–4 weeks, then taper by ~5 mg every 1–2 weeks if responding; total induction ~8–12 weeks, then consider maintenance in relapse-prone patients. Purpose: quickly reduce inflammation, relieve jaundice/pain, shrink pancreatic swelling. Mechanism: broad immune suppression, down-regulates cytokines and IgG4-rich lymphoplasmacytic infiltration; reverses ductal narrowing. Side effects: high sugar, mood/sleep change, infection risk, bone loss, fluid retention, blood pressure rise, gastric irritation; taper to avoid adrenal suppression. PMC+1

2) Low-dose steroid maintenance (selected type 1 AIP) – Class: glucocorticoid maintenance. Dose/time: e.g., 2.5–10 mg/day prednisolone for up to 3 years in relapse-prone type 1 AIP, then reassess. Purpose: prevent early relapses after induction. Mechanism: keeps immune activity suppressed at low level. Side effects: long-term steroid toxicities (bone, glucose, cataracts, skin); use bone/diabetes prevention strategies. pancreapedia.org+1

3) Azathioprine (AZA) – Class: steroid-sparing immunomodulator. Dose/time: 1–2 mg/kg/day with blood-count and liver-test monitoring; check TPMT activity before starting. Purpose: maintain remission or reduce steroid exposure in relapsing AIP. Mechanism: inhibits lymphocyte proliferation. Side effects: low blood counts, liver enzyme rise, nausea, pancreatitis (rare), infection risk; requires lab monitoring. Evidence suggests AZA reduces relapse in AIP maintenance. PMC+1

4) Mycophenolate mofetil (MMF) – Class: antimetabolite immunomodulator. Dose/time: 1–2 g/day in divided doses. Purpose: alternative to AZA as a steroid-sparing agent, especially if AZA is not tolerated. Mechanism: blocks guanine synthesis in lymphocytes. Side effects: GI upset, low blood counts, infections; contraception needed due to teratogenicity. (Evidence from IgG4-RD and autoimmune liver disease suggests MMF can help maintain remission.) Spandidos Publications+1

5) 6-Mercaptopurine (6-MP) – Class: antimetabolite immunomodulator. Dose/time: 0.5–1 mg/kg/day, monitor labs; TPMT check. Purpose: alternative to AZA for maintenance. Mechanism: purine antagonist suppressing lymphocytes. Side effects: cytopenias, hepatotoxicity, nausea, rare pancreatitis; monitoring required. Spandidos Publications

6) Methotrexate (MTX) – Class: antimetabolite immunomodulator. Dose/time: 15–25 mg once weekly with folic acid. Purpose: steroid-sparing option in selected IgG4-RD cases. Mechanism: reduces lymphocyte proliferation and cytokines. Side effects: liver enzyme elevation, cytopenias, mouth sores; avoid in pregnancy; monitor labs. Spandidos Publications

7) Rituximab (RTX) – Class: anti-CD20 monoclonal antibody (B-cell depletion). Dose/time: common regimens are 375 mg/m² weekly ×4 or 1,000 mg on days 1 and 15, with re-dosing for relapse. Purpose: for steroid-dependent, relapsing, or multi-organ IgG4-RD/AIP. Mechanism: depletes B cells that present antigen and differentiate into IgG4-secreting plasma cells. Side effects: infusion reactions, infections, hypogammaglobulinemia; screen for hepatitis B reactivation. Open-label trials show high response rates in IgG4-RD. PubMed

8) Inebilizumab – Class: anti-CD19 monoclonal antibody (depletes broader B-cell lineage, including plasmablasts). Dose/time: 300 mg IV on days 1 & 15, then every 6 months (per recent trial). Purpose: steroid-sparing induction/maintenance in IgG4-RD (investigational/region-dependent availability). Mechanism: targets CD19 to reduce disease-driving B-cell populations. Side effects: infusion reactions, infections; monitor immunoglobulins. New England Journal of Medicine

9) Budesonide (selected scenarios) – Class: high first-pass steroid. Dose/time: 9 mg/day (gastro-release) has limited data; sometimes considered where systemic exposure should be minimized—but standard systemic steroids remain first-line. Purpose: experimental steroid-sparing in mild disease (discretionary specialist use). Mechanism: local glucocorticoid activity. Side effects: fewer systemic effects but still possible. Spandidos Publications

10) Cyclophosphamide (rare/rescue) – Class: alkylating agent. Dose/time: individualized in refractory multi-organ IgG4-RD. Purpose: salvage in very resistant disease under specialty care. Mechanism: broad cytotoxic immunosuppression. Side effects: cytopenias, infections, infertility risk, bladder toxicity—specialist-only. Spandidos Publications

11) Tacrolimus (selected refractory cases) – Class: calcineurin inhibitor. Dose/time: individualized with trough monitoring. Purpose: off-label steroid-sparing in complex IgG4-RD when other options fail. Mechanism: blocks T-cell activation. Side effects: kidney dysfunction, tremor, diabetes risk, infections. Spandidos Publications

12) PPI/H2 blocker (adjunct) – Class: acid suppression. Dose/time: usual GERD dosing during high-dose steroid courses or when using non-enteric PERT. Purpose: gastric protection and improve enzyme function with non-enteric formulations. Mechanism: lowers acid; protects stomach; helps enzyme activity. Side effects: headache, diarrhea; long-term use requires review. American Gastroenterological Association

13) Trimethoprim-sulfamethoxazole (TMP-SMX) for PCP prophylaxis (when indicated) – Class: antimicrobial. Dose/time: common prophylaxis SS daily or DS three times weekly during high-risk immunosuppression. Purpose: prevent Pneumocystis pneumonia when risk is high (e.g., prolonged high-dose steroids with other risk factors). Mechanism: inhibits folate pathways in Pneumocystis. Side effects: rash, kidney effects, cytopenias; check for sulfa allergy. PMC

14) Bisphosphonates (e.g., alendronate) for bone protection – Class: anti-resorptive. Dose/time: alendronate 70 mg weekly when GIOP risk is moderate-to-high per guideline. Purpose: prevent steroid-induced fractures. Mechanism: stabilizes bone by inhibiting osteoclasts. Side effects: GI irritation, rare jaw osteonecrosis (dentistry check advised). PubMed+1

15) Insulin or glucose-lowering therapy – Class: antidiabetic agents. Dose/time: individualized. Purpose: control steroid-related hyperglycemia or pancreatogenic diabetes. Mechanism: normalizes glucose to support healing and reduce infection risk. Side effects: depend on agent (hypoglycemia with insulin, etc.). PMC

16) Ursodeoxycholic acid (UDCA) (adjunct in IgG4-SC cholestasis) – Class: bile acid. Dose/time: 13–15 mg/kg/day. Purpose: improve cholestatic labs/symptoms while steroids treat the stricture. Mechanism: cytoprotective/choleretic effects. Side effects: diarrhea, weight gain. PMC

17) Antimicrobials for cholangitis – Class: antibiotics per local protocols. Dose/time: short courses if infected obstruction occurs. Purpose: treat infection around tight bile ducts before/with drainage + steroids. Mechanism: eradicates biliary pathogens. Side effects: agent-specific. PLOS

18) Vaccines (non-live) – Class: immunization. Dose/time: per schedule; ideally before rituximab/inebilizumab. Purpose: reduce serious infections during B-cell depletion. Mechanism: primes immune memory while B-cells are intact. Side effects: local reactions. PubMed

19) Analgesics (stepwise) – Class: pain medicines (acetaminophen first; cautious short NSAID use if appropriate; avoid chronic opioids when possible). Dose/time: individualized and reassessed often. Purpose: comfort while disease control evolves. Mechanism: reduces pain perception; pair with enzyme/diet therapy. Side effects: drug-specific; watch kidneys/GI with NSAIDs. MDPI

20) Proton pump inhibitor with non-enteric PERT – Class: acid suppression. Dose/time: standard PPI dosing with meals. Purpose: improves non-enteric enzyme activity in stomach/duodenum. Mechanism: raises pH so enzymes aren’t inactivated. Side effects: see #12. American Gastroenterological Association

---

Dietary molecular supplements

1) Vitamin D – Bone protection on steroids; dose guided by blood levels (often 1,000–2,000 IU/day, more if deficient). Function: improves calcium absorption and bone strength. Mechanism: endocrine effects counter steroid-induced bone loss. Endocrine+1

2) Calcium – Usually 1,000–1,200 mg/day total intake from food + supplements if needed. Function: backbone of bone health during steroid therapy. Mechanism: offsets steroid-related negative calcium balance. Endocrine

3) Fat-soluble vitamins (A, E, K) – Doses individualized after testing in EPI. Function: corrects malabsorption-related deficiencies. Mechanism: replaces nutrients not absorbed due to low enzymes. PubMed

4) Multivitamin with trace elements – Daily standard dosing. Function: general repletion in chronic pancreatitis risk. Mechanism: covers common gaps (e.g., zinc, selenium, B-complex). PubMed

5) Medium-chain triglycerides (MCT oil) – Dosing: start small (e.g., 1–2 tsp with meals) and titrate if tolerated. Function: easier-to-absorb calories when fat malabsorption is present. Mechanism: MCTs absorb directly via portal vein, less dependent on pancreatic lipase. PubMed

6) Omega-3 fatty acids (fish oil) – Typical 1–2 g/day EPA+DHA. Function: anti-inflammatory nutrition; may help triglycerides. Mechanism: shifts eicosanoids toward less pro-inflammatory mediators. (Adjunct evidence in pancreatitis nutrition; not disease-modifying for AIP.) PMC

7) Probiotics (selected products) – Doses vary by product; use clinically supported strains and avoid in severe immunosuppression. Function: gut support during nutrition therapy. Mechanism: microbiome modulation; evidence in pancreatitis is mixed—use cautiously. PMC

8) Protein supplements (whey/peptide formulas) – Dose to meet protein goals (~1.0–1.5 g/kg/day total intake). Function: preserve lean mass during flares or poor appetite. Mechanism: high-quality amino acids, easier digestion if peptide-based. PubMed

9) Water-miscible ADEK formulations – For people with fat-malabsorption needing special forms. Dose per product. Function: better absorption of fat-soluble vitamins. Mechanism: micellized preparations bypass limited bile/enzymes. PubMed

10) Magnesium – Correct if low (dose guided by labs). Function: supports energy metabolism and may help cramps on diuretics/steroids. Mechanism: electrolyte repletion. PubMed

---

Immunity booster / regenerative / stem-cell” drugs

There are no approved “stem-cell” drugs for AIP. What is evidence-based are targeted B-cell therapies used by specialists for IgG4-RD. Below are six agents often discussed; only the first two have strong data for IgG4-RD.

1) Rituximab – See above. Dose: 375 mg/m² weekly ×4 or 1,000 mg ×2 two weeks apart; re-dose for relapse. Function: induces/maintains remission when steroids fail or aren’t tolerated. Mechanism: B-cell depletion (anti-CD20). PubMed

2) Inebilizumab – Dose: 300 mg day 1 & 15, then every 6 months. Function: steroid-sparing option under specialist care. Mechanism: broader B-cell lineage depletion (anti-CD19, includes plasmablasts). New England Journal of Medicine

3) Methotrexate – Dose: 15–25 mg weekly + folate. Function: steroid-sparing in select multi-organ disease. Mechanism: lymphocyte proliferation blockade. (Supportive but less robust evidence.) Spandidos Publications

4) Azathioprine – Dose: 1–2 mg/kg/day. Function: relapse prevention as maintenance. Mechanism: antimetabolite immunomodulation. PMC

5) Mycophenolate mofetil – Dose: 1–2 g/day. Function: alternative steroid-sparing maintenance. Mechanism: inhibits lymphocyte nucleotide synthesis. Spandidos Publications

6) Cyclophosphamide (rare) – Dose: individualized. Function: rescue therapy in refractory, organ-threatening disease; specialist-only. Mechanism: potent cytotoxic immunosuppression. Spandidos Publications

---

Surgeries / procedures

1) Endoscopic biliary stenting (ERCP) – Temporarily opens tight bile ducts to relieve jaundice/infection while steroids shrink inflammation. Usually short-term and coupled with steroid therapy. PLOS

2) ERCP tissue sampling – Brushings/biopsies to exclude cholangiocarcinoma when imaging is unclear. e-ce

3) EUS-guided pancreatic biopsy – Obtains tissue to confirm AIP and rule out cancer if imaging/serology are not decisive. PubMed

4) Surgical management (rare today) – Pancreatic resection was more common before AIP was well recognized; now reserved for cases where cancer cannot be excluded despite exhaustive work-up. PubMed

5) Biliary reconstruction (very rare) – If strictures do not respond to medical/endoscopic therapy or if there are recurrent complications, specialized surgery may be considered. PMC

---

Preventions

1. Don’t self-start/stop steroids—follow a taper plan. PMC

2. Avoid alcohol completely. Gastro Journal

3. Quit smoking and secondhand smoke exposure. PMC

4. Keep vaccines up to date before B-cell therapy when possible. PubMed

5. Protect bones on any steroid course >3 months (calcium, vitamin D, exercise; consider bisphosphonates as indicated). PubMed

6. Take enzymes with meals if you have EPI; adjust dose with your clinician. PubMed

7. Plan regular follow-ups—relapse is common in type 1. BioMed Central

8. Treat bile-duct infections quickly; don’t delay if fever/jaundice develops. PLOS

9. Ask about PJP prophylaxis if on high-dose steroids plus other risks. PMC

10. Coordinate all medications with your specialist team to avoid interactions and duplications. Spandidos Publications

---

When to see a doctor

Call your doctor promptly for new jaundice, fever/chills, worsening abdominal pain, vomiting, very light-colored stools or dark urine, rapid weight loss, high blood sugars, or severe fatigue on steroids. These may signal a flare, bile-duct infection/obstruction, or steroid complications that need urgent attention. PLOS+1

---

What to eat and what to avoid

Eat: regular, balanced meals; enough protein; fruits/vegetables; whole-grain carbs; and fats matched to your enzyme plan (many people can tolerate moderate fat if PERT is optimized). Consider MCT oil in EPI for extra calories. Hydrate well. PubMed+1
Avoid/limit: alcohol, tobacco, very high-fat meals if they trigger symptoms, and very high-fiber meals if they worsen steatorrhea when enzyme dosing is not optimal. Work with a dietitian to personalize the plan. PMC

---

Frequently asked questions (FAQ)

1) Is AIP cancer?
No. AIP is an immune-mediated inflammation, but it can look like cancer on scans; that’s why criteria (ICDC) and, at times, biopsies are used to be sure. PubMed

2) What’s the main difference between type 1 and type 2 AIP?
Type 1 is part of IgG4-RD and often relapses; type 2 is pancreas-only, often in younger people with IBD, and relapses less. PMC

3) Do most people improve on steroids?
Yes. Induction steroids lead to rapid clinical and radiologic improvement in the vast majority of patients. PMC

4) Why might I need maintenance therapy?
Because type 1 AIP relapses are common over years; maintenance (low-dose steroids or immunomodulators) can prevent frequent flares in selected people. BioMed Central

5) Are biologics like rituximab safe?
They can be effective for steroid-dependent or refractory disease, but they increase infection risk and require specialist monitoring and vaccine planning. PubMed

6) Will I always need enzymes?
Only if you have exocrine pancreatic insufficiency. Your doctor will decide based on symptoms and tests; enzymes are key to prevent malnutrition when EPI is present. PubMed

7) Can diet alone cure AIP?
No. Diet supports healing and nutrition, but immune-directed therapy treats the disease process. PMC

8) Is alcohol “in moderation” okay?
No—complete abstinence is safest in pancreatitis. Gastro Journal

9) Should I worry about bones on steroids?
Yes. Discuss calcium, vitamin D, exercise and, when indicated, medicines to prevent fractures. PubMed

10) How are bile-duct problems handled?
Tight ducts from IgG4-related cholangitis often improve with steroids; short-term stents may be needed if there’s severe jaundice or cholangitis. PLOS+1

11) What blood tests are followed?
IgG4 levels (mainly in type 1), liver tests if bile ducts are involved, and routine safety labs when on immunosuppression. PMC

12) Could I need surgery?
Rarely, mostly if cancer can’t be ruled out or complications persist despite medical/endoscopic care. PubMed

13) What if steroids raise my sugar?
Your team will adjust diet/medicines; sometimes temporary insulin is needed. Don’t stop steroids without advice. PMC

14) Are there new treatments coming?
Yes—B-cell–directed therapies like inebilizumab have encouraging data in IgG4-RD. Availability depends on region/trials. New England Journal of Medicine

15) How often should I follow up?
Early after diagnosis, visits are frequent during induction; later, interval depends on relapse risk and organs involved. Your team will personalize a plan using consensus criteria. PubMed+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.